MARKET

STSA

STSA

SATSUMA PHARMACEUTICALS
NASDAQ

Real-time Quotes | Nasdaq Last Sale

20.82
+1.22
+6.22%
Opening 10:25 01/28 EST
OPEN
19.69
PREV CLOSE
19.60
HIGH
20.82
LOW
19.69
VOLUME
14.91K
TURNOVER
--
52 WEEK HIGH
21.60
52 WEEK LOW
8.61
MARKET CAP
335.31M
P/E (TTM)
-17.5400
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of STSA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

STSA News

  • The Daily Biotech Pulse: Canadian Approval For Amarin's Vascepa, Innate Pharma's Blood Cancer Drug Accepted For Review In Europe
  • Benzinga.01/02 13:52
  • Hedge Funds Have Never Been This Bullish On Satsuma Pharmaceuticals, Inc. (STSA)
  • Insider Monkey.12/16/2019 18:47
  • Satsuma Pharmaceuticals to Present at the 2nd Annual Evercore ISI HealthCONx Conference
  • GlobeNewswire.11/26/2019 12:00
  • Satsuma Pharmaceuticals Q3 EPS $(2.26) Down From $(1.48) YoY
  • Benzinga.11/12/2019 21:04

More

Industry

Biotechnology & Medical Research
+1.42%
Pharmaceuticals & Medical Research
+0.75%

Hot Stocks

Name
Price
%Change

About STSA

Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a therapeutic product for the treatment of migraine. The Company’s product candidate STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate (DHE), which can be self-administered with a proprietary pre-filled, single-use, nasal delivery device.
More

Webull offers Satsuma Pharmaceuticals Inc (STSA) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.